Eligo Bioscience

Overview
News
Human Gene Editing?
Product stageSegments
Seed
?
R&D therapies: CRISPR/Cas9 technology, Gene editing: SaaS platforms
?

Based in France, Eligo Bioscience develops novel microbiome gene editing therapies across various therapeutic areas including autoimmunology, dermatology, and oncology using the CRISPR technology including base editing. The company’s approach entails editing microbiome gene ​​repertoire to add or remove genes to support disease treatment. For this, it designs small biotherapeutics dubbed eligobiotics, made out of DNA and proteins to target specific parts of the bacteria.

The company has not revealed its complete pipeline of therapeutic programs. It leverages its three proprietary eligobiotics platforms: 1) Sequence-Specific Anti-Microbials (SSAM) to deliver CRISPR-Cas9 nucleases and the corresponding guide RNA into the genome, which will only eliminate the unfavorable parts of the bacteria and leave the favorable ones unaffected; 2) Gene-Editing of the Microbiome (GEM) platform to deliver base editors into the bacteria to modify the genome, without destroying the bacteria; and 3) Function Addition to the MicrobiomE (FAME) to deliver a therapeutic gene into the microbiome to trigger existing microbial populations to stimulate a therapeutic impact in the body.

Key customers and partnerships

Eligo entered into a USD 224 million partnership with GlaxoSmithKline in January 2021 to leverage its eligobiotics technology to prevent acne vulgaris, a skin condition, and received funding for its acne program EB0005. Both parties also planned to enter into a licensing and collaboration agreement. 

In June 2020, Eligo Bioscience secured USD 7.1 million investment—including milestone payments—from CARB-X , a global non-profit organization, to develop highly specific antimicrobials to prevent multi-drug-resistant bacterial infections in organ transplant patients. 

Funding and financials

In December 2023, Eligo Bioscience raised USD 30 million in a Series B funding round led by Sanofi Ventures, with participation from new investor Bpifrance (through its InnoBio 2 fund) and existing investors Khosla Ventures and Seventure Partners. The proceeds were set aside to accelerate the development of Eligo’s primary program, EB005, designed for acute acne and to facilitate pre-Investigational New Drug (IND) and IND activities to achieve early human data readouts in a Phase Ib/IIa clinical trial. The funding was also set aside to support Eligo’s expansion into other chronic diseases, including oncology.

HQ location:
Paris FRA
Founded year:
2014
Employees:
11-50
IPO status:
Private
Total funding:
USD 69.7 mn
Last Funding:
USD 29.9 mn (Series B; Dec 2023)
Last valuation:
-
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.